PRINCETON, N.J. & REHOVOT, Israel--(BUSINESS WIRE)--Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces that the Company was granted conditional approval status for its ROS1 lung cancer biomarker by Fluorescence in situ Hybridization (FISH) assay from the New York State Department of Health (“NYSDOH”) under the Company’s Molecular Oncology permit. New York is the only U.S. state that requires an independent regulato